Pearl IRB announces the hiring of Mark Slisz as a Senior Advisor serving biopharmaceutical, medical device, and diagnostic life science companies. Slisz brings over 35 years of experience in the pharmaceutical industry to Pearl Pathways. His experience includes protein purification and characterization, recombinant DNA technology, large scale biotechnology purification and development, active ingredient and drug product manufacturing including sterile manufacturing, and regulatory affairs.
Prior to joining Pearl Pathways, Mark Slisz directed the CMC regulatory strategy and risk assessment for Endocyte, Inc., a small biopharmaceutical company that pairs companion imaging agents with small molecule drug conjugates for cancer treatment. Before Endocyte, Mark held roles in regulatory, manufacturing, process development, and research at Eli Lilly and Company.
Diana Caldwell, President and CEO shares, “Our clients will benefit from Mark’s extensive leadership experience navigating a variety of regulatory compliance challenges in large multi-national companies and small startups… we are thrilled to have Mark join our team.”